Table 1.
Patient and tumor characteristics
| Patient and tumor characteristics | AED withdrawal group (n = 46) (%) |
AED continuation group (n = 25) (%) |
Sign (p-value) |
|---|---|---|---|
| Age (mean years, range) | 50 (24–72) | 53 (28–79) | 0.24 |
| Hospital | < 0.005 | ||
| VUmc | 18 (39) | 4 (16) | |
| HMC | 18 (39) | 4 (16) | |
| EMC | 10 (22) | 17 (68) | |
| Diagnosed (mean years, range) | 7.2 (3.1–19.5) | 7.9 (3.8–15.7) | 0.12 |
| WHO grade glioma | 0.20 | ||
| Grade II | 24 (52) | 17 (68) | |
| Grade III | 22 (48) | 8 (32) | |
| LOH 1p/19q | 0.40 | ||
| 1p/19q codeleted | 18 (39) | 11 (44) | |
| 1p/19q not codeleted | 13 (28) | 9 (36) | |
| Unknown | 15 (33) | 5 (20) | |
| Type epilepsy | 0.59 | ||
| Focal to bilateral tonic clonic | 21 (46) | 12 (48) | |
| Focal | 10 (22) | 3 (12) | |
| Combination | 9 (20) | 2 (8) | |
| Unknown | 6 (13) | 8 (32) | |
| Duration seizure free before inclusion (median years, range) | 2.9 (1–12.8) | 4.1 (1–20) | 0.06 |
| Tumor progression before inclusion | 0.12 | ||
| No progression | 35 (76) | 22 (88) | |
| ≥ One progression | 11 (24) | 3 (12) | |
| Latest anti-tumor treatment | 0.25 | ||
| Surgery | 6 (13) | 2 (8) | |
| Radiotherapy | 26 (57) | 11 (44) | |
| Chemotherapy | 14 (30) | 13 (52) | |
| AED use | 0.57 | ||
| VPA | 10 (22) | 6 (24) | |
| LEV | 27 (59) | 14 (56) | |
| LAM | 2 (4) | 1 (4) | |
| PHT | 3 (7) | 0 (0) | |
| CBZ | 3 (7) | 4 (16) | |
| LAC | 1 (2) | 0 (0) | |
| Type therapy | 0.24 | ||
| Monotherapy | 40 (87) | 19 (76) | |
| Polytherapy (> 1 AED) | 6 (13) | 6 (24) |
AED antiepileptic drug, VPA valproic acid, LEV levetiracetam, LAM lamotrigine, PHT phenytoin, CBZ carbamazepine, LAC lacosamide